Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phenotypic Drug Screening for Novel Antifibrotic Therapeutics in Lung Health.

Methods in molecular biology (Clifton, N.J.) - 1 Jan 2026

Wei Xin, Verma Arun Kumar, Merchant Kevin, Porras-Gonzalez Diana, Jäger Joshua, Wögrath Melanie, Shen Lin, Yildirim Ali Önder, Gerckens Michael, Burgstaller Gerald

Abstract excerpt

Lung diseases are among the leading causes of death worldwide. Still, noncommunicable pulmonary diseases, such as chronic obstructive pulmonary disease (COPD), and interstitial lung disease (ILD), are lacking curative pharmacotherapies. Either degradation or excessive production of altered pulmonary extracellular matrix (ECM) is a common key feature of those devastating diseases, respectively. Recapitulating...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cells, Cultured
Share to Drug Discovery

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Evaluation, Preclinical

Share to Extracellular Matrix

Share to Fibroblasts

Share to High-Throughput Screening Assays

Share to Pulmonary Fibrosis

Source

Identifiers

PMID: 41479055
DOI: 10.1007/978-1-0716-4985-5_11

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phenotypic Drug Screening for Novel Antifibrotic Therapeutics in Lung Health.PMID 41479055Read ↗

Fibrotic human lung extracellular matrix as a disease-specific substrate for 3D <i>in-vitro</i> models of pulmonary fibrosisSemantic proximity Read ↗

Targeting the epithelium in pulmonary fibrosis.Semantic proximity Read ↗

Enhancing throughput and robustness of the fibroblast to myofibroblast transition assaySemantic proximity Read ↗

Biofabrication of phenotypic pulmonary fibrosis assays.Semantic proximity Read ↗

Comprehensive Analysis of Fibroblast Activation Protein Expression in Interstitial Lung DiseasesSemantic proximity Read ↗

Current and Future Treatment Landscape for Idiopathic Pulmonary Fibrosis.Semantic proximity Read ↗

Fibroblast phenotypes in pulmonary fibrosis.Semantic proximity Read ↗

The progressive fibrotic phenotype in current clinical practice.Semantic proximity Read ↗

In Vitro Modeling of Idiopathic Pulmonary Fibrosis: Lung-on-a-Chip Systems and Other 3D CulturesSemantic proximity Read ↗

Cell-Specific Modulation of the Aryl Hydrocarbon Receptor by Kynurenine in Pulmonary Fibrosis Requires Microenvironmental CrosstalkSemantic proximity Read ↗

Inhibition of fibrosis with multi-agent therapy in pulmonary fibrosis: Results of a drug library screeningSemantic proximity Read ↗

Phenotypic drug screening in a human fibrosis model identified a novel class of antifibrotic therapeuticsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.